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To enhance the dissolution of poorly soluble mefenamic acid, self-emulsifying formulation
(SEF), composing of oil, surfactant and co-surfactant, was formulated. Among the oils and
surfactants studied, Imwitor® 742, Tween® 60, Cremophore® EL and Transcutol® HP were
selected as they showed maximal solubility to mefenamic acid. The ternary phase diagram
was constructed to find optimal concentration that provided the highest drug loading. The
droplet size after dispersion and drug dissolution of selected formulations were investi-
gated. The results showed that the formulation containing Imwitor® 742, Tween® 60 and
Transcutol® HP (10:30:60) can encapsulate high amount of mefenamic acid. The dissolution
study demonstrated that, in the medium containing surfactant, nearly 100% of mefenamic
acid were dissolved from SEF within 5 min while 80% of drugs were dissolved from the
commercial product in 45 min. In phosphate buffer (without surfactant), 80% of drug were
dissolved from the developed SEF within 5 min while only about 13% of drug were dis-
solved in 45 min, from the commercial product. The results suggested that the SEF can
enhance the dissolution of poorly soluble drug and has a potential to enhance drug ab-
sorption and improve bioavailability of drug.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Mefenamic acid, a non-steroidal anti-inflammatory drug
(NSAID) of the enolic acid class, is widely used in mild toaceutical Technology, Fa
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plasma levels ranging from 10 to 20 mg/ml have been re-
ported. Peak plasma levels are attained in 2e4 h and the
elimination half-life approximates 2 h [2,3]. Mefenamic acid
belongs to class II category under the biopharmaceutical
classification system (BCS), i.e., it is inherently highly
permeable through biological membranes, but exhibits low
aqueous solubility. Rate of absorption and/or extent of
bioavailability for such insoluble hydrophobic drug are
controlled by rate of dissolution in gastro-intestinal fluids.
However, its oral bioavailability is very low, probably due to
poor solubility in water and insufficient dissolution rate [1e3].
Various approaches for improving drug dissolution rate
have been reported in literature, including reducing the par-
ticle size, solid dispersion, inclusion complex formation, sol-
ubilization in surfactant system, using prodrugs and drug
derivatization, lipid-based formulation, and self-emulsifying
drug delivery system [4]. Among these approaches, self-
emulsifying drug delivery system (SEDDS) is found to be a
prominent approach to improve solubility and drug dissolu-
tion. SEDDS is an isotropic mixture of oil, surfactant, co-
surfactant and drug, which spontaneously forms thermody-
namically stable oil-in-water emulsionswhen introduced into
aqueous phase under gentle agitation conditions, similar to
those which would be encountered in the GI tract [5e7].
Poorly water-soluble drugs can be dissolved in SEDDS,
allowing them to be encapsulated as dosage form for oral
administration. Upon contact with aqueous phase of GI tract,
the SEDDS formulations are self-emulsifying and very fine
dispersions are then formed spontaneously with the aid of GI
motility [8] because the free energy required to form the
emulsion is either low and positive or negative. Therefore, the
drug remains in solution in the GI lumen, avoiding the
dissolution step which often limits the rate of absorption of
poorly water-soluble drugs from the crystalline state [9].
SEDDS appears to be an attractive choice of formulation as it
requires simple manufacturing equipment. This is because it
is physically stable lipid-based solution and omits the need of
high energy emulsification process, and thus reduces the
manufacturing cost. Moreover, greater dissolution rate of
SEDDS reveals the reduction in drug dose and possibly reduce
the dose-related side effects.
In this study, we developed a new self-emulsifying
formulation (SEF) of mefenamic acid to enhance the dissolu-
tion rate of mefenamic acid. Physical properties and dissolu-
tion profiles of SEF were evaluated in comparison to
mefenamic acid powders and commercial capsules.2. Materials and methods
2.1. Materials
Mefenamic acid, clove oil, olive oil and rice bran oil were
purchased from P.C. Drug Center (Thailand). Caprylic/capric
triglycerides (Miglyol® 812) and caprylic/capric glyceride
(Imwitor® 742) were purchased form Sasol (Germany). Oleic
acid was purchased from SigmaeAldrich (USA). Polyoxy-
ethylene 20 sorbitan monolaurate (Tween® 20), Polyoxy-
ethylene (20) sorbitan monostearate (Tween® 60),polyoxyethylene 20 sorbitan monooleate (Tween® 80), sorbi-
tan monolaurate (Span® 20) and sorbitan monostearate
(Span® 60) were purchased from Fluka (USA). Polyoxyl 40 hy-
drogenated castor oil (Cremophor® RH40) and polyoxyl 35
castor oil (Cremophor® EL) were a gift form BASF (Thai) Co.,
Ltd. (Thailand). Diethylene glycolmonoethyl ether (Trans-
cutol® HP) was supported by Gattefosse (Saint-Priest Cedex,
France). Other chemicals were of reagent or analytical grade
and used without further purification. Distilled water was
used in all preparations.
2.2. Determination of drug solubility in various vehicles
Solubility of mefenamic acid was determined in various ve-
hicles by adding excess amount ofmefenamic acid (500mg) in
10 mL of a pure vehicle in glass tubes. The drug suspension
was equilibrated at 25 C in a thermostatically controlled bath
for 72 h. After equilibration, the tubes were centrifuged at
12,000 rpm for 20 min and the clear supernatants were
analyzed for mefenamic acid with a high performance liquid
chromatography (HPLC, model JASCO PU-2089 plus quater-
nary gradient inert pump, and a JASCO UV-2070plus multi-
wavelength UVevis detector, Jasco, Japan) using Luna 5u C18
column (5 mm, 4.6 nm  25 cm) (Phenomenex, USA). The
mobile phase composing of acetonitrile, pH 5.0 phosphate
buffer and tetrahydrofuran (23:20:7) was filtered through a
0.22-mm membrane filter, and degassed in a sonicator bath
before use. The flow rate of mobile phase was 1 mL/min, and
the UV detection wavelength was 254 nm.
2.3. Construction of ternary phase diagram and
preparation of SEF
Based on the solubility studies, the oil (Imwitor® 742), sur-
factant (Tween® 60 or Cremophor® EL) and co-surfactant
(Transcutol® HP) were chosen for the construction of ternary
phase diagram. A series of SEF were prepared using various
concentrations (10e80% v/v) of oil, surfactant and co-
surfactant. The oil, surfactant and co-surfactant were mixed
at ambient temperature (25 C), until clear solution was ob-
tained. Then, excess amount of mefenamic acid (500 mg) was
added to the mixtures and mixed thoroughly. The resultant
formulations were shaken at ambient temperature (25 C) for
72 h, in the same manner as mentioned above, before further
analysis of mefenamic acid content, as described above.
2.4. Physical characterization
Visual observation of self-emulsification: Evaluation of the
self-emulsifying properties of SEF was visually observed (i.e.,
until a clear homogenous system was obtained).
Droplet size analysis: The droplet size of emulsion formed
after reconstitution of SEF in water (200 times) was deter-
mined by static laser light scattering (model LA-950, Horiba,
Japan). Reconstituted samples were withdrawn and diluted to
a final concentration of approximately 0.05% (w/w) with
distilled water. A relative refractive index of 1.2 (ratio of the
indices between the oil and water phase) was used. All mea-
surements were repeated 3 times and the values of mean
diameter were reported. The span, which is the width of the
Table 1 e Solubility of mefenamic acid in various vehicles
(n ¼ 3).
Vehicle Solubility (mg/ml)
Distilled water 0.01 ± 0.01
Oils
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calculated from the following equation:
Span ¼ D½v;0:9 D½v; 0:1
D½v; 0:5
where D(v,0.5) is the volume median diameter where 50% of
the volume distribution is above and 50% is below, D(v,0.9) is
the volume median diameter where 90% of the distribution is
below this value, and D(v,0.1) is the volume median diameter
where 10% of the volume distribution is below this value.
2.5. In vitro dissolution study
The in vitro dissolution of mefenamic acid from SEF formula-
tions was compared to that of mefenamic acid powder and
commercial product (mefenamic acid capsules) purchased
from the retail pharmacy in Thailand. The dissolution test
was carried out using USP dissolution apparatus I (PharmaT-
est, Germany) with 900 mL of 0.05 M Tris buffer (pH 9.0) with
1% (w/v) sodium lauryl sulfate (SLS) or phosphate buffer (pH
7.4) as dissolution medium at 37 ± 0.5 C. The basket rotation
speed was adjusted to 100 rpm. Selected drug-loaded SEF
formulations (equivalent to 250 mg of mefenamic acid) filled
in hard capsules were put into a basket before placing in a
dissolution vessel. During the study, 5 mL aliquots were
removed at predetermined time intervals from the dissolution
medium and 5 mL of fresh medium were replaced. Samples
were withdrawn from the dissolution vessels at 2, 5, 10, 20, 30,
45 and 60 min, and passed through 0.45-mm nylon membrane
filters before analysis. The amount of mefenamic acid dis-
solved in the dissolutionmediumwas determined by HPLC, as
mentioned above. The dissolution experiments were carried
out in triplicate.
2.6. Statistical analysis
Analysis of variance (ANOVA) and Levene's test for homoge-
neity of variance were carried out using SPSS version 10.0 for
Windows (SPSS Inc., USA). Post hoc testing (P < 0.05) of the
multiple comparisons was performed by either the Scheffe or
GameseHowell test depending on whether Levene's test was
insignificant or significant, respectively.Clove oil 9.95 ± 0.68
Olive oil 2.24 ± 0.49
Rice bran oil 2.36 ± 0.03
Imwitor® 742 7.88 ± 0.62
Miglyol® 812 3.30 ± 3.07
Oleic acid 5.90 ± 0.46
Surfactants
Span® 20 6.07 ± 0.52
Span® 60 6.82 ± 0.76
Tween® 20 36.96 ± 1.20
Tween® 60 44.60 ± 0.52
Tween® 80 31.94 ± 0.58
Cremophor® EL 37.62 ± 2.76
Cremophor® RH 36.59 ± 3.06
Labrasol® 25.96 ± 3.12
Co-surfactants/cosolvents
Transcutol® HP 38.76 ± 2.42
PEG 400 29.79 ± 3.07
PEG 600 26.63 ± 2.62
PG 0.82 ± 0.213. Results and discussion
3.1. Solubility of mefenamic acid in various vehicles
As oil, surfactant and co-surfactant play a vital role to increase
the solubility of drug and drug loading in SEF, these compo-
nents should be carefully chosen to have maximal drug sol-
ubility along with good miscibility with each other to produce
a stable formulation [10]. The solubility of mefenamic acid in
various vehicles is presented in Table 1. Higher solubility of
mefenamic acid in the oil phase was important criterion, as it
could help the emulsion to maintain drug in solubilized form.
Mefenamic acid exhibited high solubility in clove oil
(9.95 ± 0.68 mg/ml) but this oil can irritate mucus membranes
and cause skin irritation. Thus, it is not suitable for using as oil
phase in SEF. It is shown that the solubility of mefenamic acidin Imwitor® 742 was high (7.88 ± 0.62 mg/ml), as Imwitor® 742
(caprylic/capric glyceride) is amphiphilic compound with
surface active property. In addition, some hydroxyl groups
within the glycerol ester of Imwitor® 742 are free, contributing
to its polarity and excellent solvent properties formany drugs.
Therefore, Imwitor® 742 was then selected as an oil compo-
nent for further study.
Various non-ionic surfactants have been widely used due
to their relatively low toxicity. The results shown in Table 1
suggest that mefenamic acid was highly soluble in hydro-
philic surfactant, e.g., Tween® and Cremophor®. Tween® 60
was found to have the maximal solubilizing capacity
(44.60 ± 0.52 mg/ml) while Span® 20 demonstrated the mini-
mal solubilizing capacity (6.07 ± 0.52 mg/ml) for mefenamic
acid. Cremophor® EL also showed high drug solubility
(37.62 ± 2.76 mg/ml). It is observed that mefenamic acid was
highly soluble in co-surfactant; the highest solubility was
found in Transcutol® HP (38.76 ± 2.42 mg/ml). Based on the
solubility of mefenamic acid in different oils, surfactants and
co-surfactants, we have selected Imwitor® 742 as oil, Cremo-
phor® EL and Tween® 60 as surfactant and Transcutol® HP as
co-surfactant for the preparation of SEF.
3.2. Preparation of SEF
Ternary phase diagrams were constructed to obtain the
appropriate components of oil, surfactant and co-surfactant
that can result in spontaneously formed emulsion. Surfac-
tant and co-surfactant are preferentially adsorbed at the
interface, reducing the interfacial energy as well as providing
a mechanical barrier to coalescence. Fig. 1 shows the ternary
phase diagram of Imwitor® 742, Cremophor® EL or Tween®
60, and Transcutol® HP. Fourteen different combinations for
each surfactant (Cremophor® EL or Tween® 60) were pre-
pared. It was observed that the incorporation of high
Fig. 1 e Ternary phase diagram of Imwitor® 742, Cremophor® EL or Tween® 60, and Transcutol® HP.
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the spontaneity of the spontaneous emulsification process,
as shown by the highlighted region in the ternary phase di-
agram (Fig. 1). The efficiency of emulsification was goodTable 2 e Maximal drug loading in different self-emulsifying f
Formulation Imwitor® 742 (%) Cremophor® EL (%) Tween®
C1 10 80 e
C2 10 40 e
C3 10 10 e
C4 40 10 e
C5 80 10 e
C6 50 40 e
C7 30 30 e
C8 10 30 e
C9 10 20 e
C10 20 10 e
C11 30 10 e
C12 30 20 e
C13 20 30 e
C14 20 20 e
T1 10 e 80
T2 10 e 40
T3 10 e 10
T4 40 e 10
T5 80 e 10
T6 50 e 40
T7 30 e 30
T8 10 e 30
T9 10 e 20
T10 20 e 10
T11 30 e 10
T12 30 e 20
T13 20 e 30
T14 20 e 20
Note: N/A ¼ not applicable.when the surfactant/co-surfactant concentration was more
than 50% (v/v) of the SEF.
The solubility of mefenamic acid in each formulation was
consequently determined (Table 2). It is clearly seen that theormulations (n ¼ 3).
60 (%) Transcutol® HP (%) Maximal drug loading (mg/ml)
10 25.19 ± 0.66
50 31.84 ± 0.70
80 36.04 ± 1.78
50 19.41 ± 4.02
10 14.49 ± 1.19
10 17.85 ± 0.36
40 24.85 ± 0.79
60 29.60 ± 0.58
70 34.71 ± 2.07
70 14.45 ± 3.44
60 12.57 ± 0.68
50 18.17 ± 2.38
50 17.72 ± 4.50
60 20.88 ± 4.65
10 24.74 ± 0.78
50 31.70 ± 1.19
80 30.89 ± 1.64
50 24.77 ± 0.79
10 11.08 ± 0.77
10 16.79 ± 1.18
40 N/A
60 34.59 ± 0.12
70 30.50 ± 0.04
70 32.90 ± 0.12
60 28.07 ± 1.14
50 31.34 ± 1.51
50 30.78 ± 1.46
60 32.12 ± 0.25
Table 3 e Droplet size of self-emulsifying formulations selected, after dispersion in water (n ¼ 3).
Formulation Imwitor® 742 (%) Cremophor® EL (%) Tween® 60 (%) Transcutol® HP (%) Droplet size (mm) Span
C3 10 10 e 80 10.83 ± 0.12 2.36
C8 10 30 e 60 7.18 ± 0.01 1.35
T3 10 e 10 80 20.37 ± 1.45 1.59
T8 10 e 30 60 7.20 ± 0.01 1.53
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phor® EL or Tween® 60) and those with high concentration of
oil (Imwitor® 742) had a low drug loading capacity. Higher drug
loading was obtained from the formulations with high con-
centration of co-surfactant (Transcutol®HP). The results are in
good agreement with those reported by Weerapol et al. [11].
Exception is for T7, which the appearance of the mixture
changed to viscous gel-like appearance and the drug content
was not determined.
The spontaneous emulsifying properties of selected for-
mulations providing high drug loading, i.e., C3, C8, T3 and
T8, were observed visually as well as by droplet size analysis.
It is noticeable that these formulations still remain as clear
mixture after diluting with water (200 times). This is prob-
ably because the surfactant and co-surfactant can be
adsorbed at the interface of oil and water and stabilized the
formation of emulsions. Turbid, milky emulsions were
observed as their droplet size was in micrometer range
(Table 3). The droplet size of SEF containing mefenamic acid
was larger than the SEF with no drug and with other drugs,
prepared in our previous study [11]. Additionally, small span
values were obtained, indicating a narrow size distribution
[12].
3.3. In vitro dissolution study
The dissolution of mefenamic acid, in 0.05 M Tris buffer (pH
9.0) with 1% (w/v) SLS according to USP monograph for
mefenamic acid capsules, from SEF was compared with that
ofmefenamic acid powder and commercial product (Fig. 2). As0
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Fig. 2 e Dissolution profiles of mefenamic acid powders and se
with 1% (w/v) sodium lauryl sulfate (n ¼ 3).stated in the USP, the dissolution of mefenamic acid from the
mefenamic acid capsules in 45 min should be not less than
80%. It is clearly seen that the dissolution, in 45 min, of
mefenamic acid powder was about 57% while that of the
commercial product conformed to the monograph (i.e., about
80% dissolved). The dissolution from C3 and T8 demonstrated
improved drug dissolution; the drug dissolution from these
formulations seemed to reach nearly 100% immediately,
suggesting the increased solubility and dissolution rate of
mefenamic acid. This may result from a fast spontaneous
emulsion formation and the small droplet size [13]. Interest-
ingly, the lower drug dissolution with a decline phase was
observed from C8 and T3. It is possible that C8 and T3 for-
mulations induced the generation of supersaturated solution
of mefenamic acid. Brouwers et al. [14] suggested that the
drugs in highly concentrated solution (including SEF) are
thermodynamically unstable and have a tendency to precip-
itate in the medium.
The dissolution in pH 7.4 phosphate buffer showed
different dissolution profiles (Fig. 3); the dissolution of mefe-
namic acid powder was very low, less than 5% dissolved in
60min. The drug dissolution, in pH 7.4 phosphate buffer, from
commercial product was also low (only about 14% dissolved in
60 min). The results agreed with that reported by Vikram et al.
[15], which the dissolution of commercial mefenamic acid
tablets, performed in pH 7.4 phosphate buffer, shows a
maximum drug dissolution of 51% in 45 min. The dissolution
of mefenamic acid from T3 and C3 (composing of
oil:surfactant:co-surfactant of 10:10:80) was approximately
30e40% in 45min while that from T8 and C8, which contained50 60
T8
C8
T3
C3
Commercial product
Mefenamic acid powder
lf-emulsifying formulations, in 0.05 M Tris buffer (pH 9.0)
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Fig. 3 e Dissolution profiles of mefenamic acid powders and self-emulsifying formulations, in pH 7.4 phosphate buffer
(n ¼ 3).
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60e80% in 45 min). The formation of fine emulsion droplets
would be attributable to improved drug dissolution, which
might partly explain the more rapid dissolution of SEF con-
taining higher concentration of surfactant. Furthermore, the
dissolution results showed that the SEF containing Tween® 60
as surfactant presented a higher drug dissolution than that
containing Cremophor® EL, at the same oil:surfactant:co-
surfactant ratio. It is likely due to the higher hydro-
philicelipophilic balance (HLB) value of Tween® 60 (HLB 14.9),
compared to Cremophor® EL (HLB 13). With the higher HLB
values, hydrophilicity of surfactants was increased. An in-
crease in water solubility and hydrophilicity of surfactants
could increase the rate of drug dissolution and diffusion to the
dissolution medium [16].4. Conclusion
SEF composing of oil, surfactant and co-surfactant was used
to improve the dissolution of mefenamic acid. The optimal
concentration of components that provided high drug loading
was determined using ternary phase diagram. The formula-
tion containing Imwitor® 742, Tween® 60 and Transcutol® HP
(10:30:60) can encapsulate high amount of mefenamic acid
and demonstrated the highest drug dissolution in 45 min,
resulting from a fast spontaneous emulsion formation and
small droplet size. The developed formulations were very
simple and can be used to improve drug dissolution and,
hence, have a potential to enhance drug absorption and
bioavailability.Acknowledgments
Financial support from The Thailand Research Fund (grant
number BRG5480013) is greatly acknowledged. Thanks toBASF (Thai) Co., Ltd. (Thailand) and Gattefosse (France) who
kindly donated samples.r e f e r e n c e s
[1] Mudalip SKA, Bakar MRA, Jamal P, et al. Solubility and
dissolution thermodynamic data of mefenamic acid crystals
in different classes of organic solvents. J Chem Eng Data
2013;58:3447e3452.
[2] Rawashdeh NM, Najib NM, Jalal IM. Comparative
bioavailability of two capsule formulations of mefenamic
acid. Int J Clin Pharmacol Ther 1997;35:329e333.
[3] Shinkuma D, Hamaguchi T, Yamanaka Y, et al. Correlation
between dissolution rate and bioavailability of different
commercial mefenamic acid capsules. Int J Pharm
1984;21:187e200.
[4] Kawabata Y, Wada K, Nakatani M, et al. Formulation design
for poorly water-soluble drugs based on biopharmaceutics
classification system: basic approaches and practical
applications. Int J Pharm 2011;420:1e10.
[5] Hintzen F, Perera G, Hauptstein S, et al. In vivo evaluation of
an oral self-microemulsifying drug delivery system
(SMEDDS) for leuprorelin. Int J Pharm 2014;472:20e26.
[6] Weerapol Y, Limmatvapirat S, Nunthanid J, et al. Self-
nanoemulsifying drug delivery system of nifedipine:
impact of hydrophilic-lipophilic balance and molecular
structure of mixed surfactants. AAPS PharmSciTech
2014;15(2):456e464.
[7] Date AA, Desai N, Dixit R, et al. Self-nanoemulsifying drug
delivery systems: formulation insights, applications and
advances. Nanomedicine 2010;5:1595e1616.
[8] Sole I, Solans C, Maestro A, et al. Study of nano-emulsion
formation by dilution of microemulsions. J Colloid Interface
Sci 2012;376:133e139.
[9] Kohli K, Chopra S, Dhar D, et al. Self-emulsifying drug
delivery systems: an approach to enhance oral
bioavailability. Drug Discov Today 2010;15:958e965.
[10] Dahan A, Hoffman A. Rationalizing the selection of oral lipid
based drug delivery systems by an in vitro dynamic lipolysis
model for improved oral bioavailability of poorly water
soluble drugs. J Control Release 2008;129:1e10.
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 1 2 1e1 2 7 127[11] Weerapol Y, Limmatvapirat S, Kumpugdee-Vollrath M, et al.
Spontaneous emulsification of nifedipine-loaded self-
nanoemulsifying drug delivery system. AAPS PharmSciTech
2015. http://dx.doi.org/10.1208/s12249-014-0238-0.
[12] Chew NY, Chan HK. Effect of powder polydispersity on
aerosol generation. J Pharm Pharm Sci 2002;5:162e168.
[13] Kang JH, Oh DH, Oh YK, et al. Effects of solid carriers on the
crystalline properties, dissolution and bioavailability of
flurbiprofen in solid self-nanoemulsifying drug delivery
system (solid SNEDDS). Eur J Pharm Biopharm
2012;80:289e297.[14] Brouwers J, Brewster ME, Augustijns P. Supersaturating drug
delivery systems: the answer to solubility-limited oral
bioavailability. J Pharm Sci 2009;98:2549e2572.
[15] Vikram A, Firoz S, Kishore D, et al. Formulation and
eveluation of mefenamic acid tablets by using modified
starch. Asian J Pharm Sci Technol 2012;2:46e53.
[16] Mohammadi-Samani S, Boostanian A. The effect of HLB on
the release profile of atenolol from ethyl cellulose-coated
tablets. Iranian J Pharm Res 2004;3:145e148.
